Aleva Neurotherapeutics SA, a Swiss company with a candidate device for deep brain stimulation, has obtained $18 million in Series C financing enabling it to prepare for the registration of its product in Europe in 2017. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
